# Ascites

New or worsening ascites requires prompt paracentesis, fluid-pattern interpretation, and early detection of spontaneous bacterial peritonitis, renal dysfunction, and portal-hypertensive decompensation. Management is driven by etiology, ascites severity, response to fluid removal, and candidacy for TIPS or liver transplantation.

**Clinical question:** How should physicians rapidly classify, investigate, and manage new or worsening ascites while identifying infection and refractory portal-hypertensive disease?

Updated: 2026-09-16T00:41:11.267757+00:00

## What matters in practice
- Perform diagnostic paracentesis in every patient with new-onset ascites and without delay in hospitalized patients with cirrhosis and ascites. [10][19]
- Use same-day serum and ascitic albumin to calculate SAAG: ≥1.1 g/dL supports portal-hypertensive ascites; combine it with ascitic total protein to distinguish cirrhosis from cardiac ascites. [10][23]
- Treat ascitic neutrophil counts >250/mm3 as spontaneous bacterial peritonitis; obtain fluid cell count with differential and culture as part of the initial tap. [19][23]
- After removal of >5 L during paracentesis for cirrhotic ascites, give 20% or 25% albumin 8 g per liter removed. [2][3]
- Refractory or recurrent ascites warrants TIPS consideration and liver-transplant assessment, but bilirubin >50 micromol/L, platelets <75 × 10^9/L, current encephalopathy, infection, renal decline, cardiac dysfunction, or pulmonary hypertension identify higher-risk TIPS candidates. [6][9]

## When ascites requires immediate diagnostic paracentesis

Do not attribute fluid accumulation to cirrhosis without fluid analysis.

Perform diagnostic paracentesis for all new-onset ascites. Obtain abdominal ultrasound before the procedure for fluid confirmation and site selection. In cirrhosis, perform the tap without delay at hospital admission and repeat diagnostic evaluation when ascites worsens or when gastrointestinal bleeding, shock, fever, systemic inflammation, gastrointestinal symptoms, worsening kidney or liver function, or hepatic encephalopathy occurs. [10][19]

Send ascitic fluid for cell count with differential, albumin, and total protein; obtain serum albumin on the same day for SAAG calculation. Send culture when infection is suspected, ideally by bedside inoculation into aerobic and anaerobic blood-culture bottles before antimicrobials. Cytology requires a larger sample than the approximately 50 mL generally sufficient for routine diagnostic studies. [11][12][23]

Ascites in cirrhosis is a decompensating event rather than an isolated symptom: five-year survival declines from approximately 80% in compensated cirrhosis to approximately 30% after ascites develops. Clinically significant ascites and associated complications should prompt consideration of liver-transplant evaluation. [19][24]
- Use ultrasound-guided site selection when fluid is limited, loculated, or the bedside examination is uncertain. [10][12]
- During a therapeutic tap in a hospitalized patient, also request ascitic cell count because SBP may coexist with symptomatic volume overload. [12]
- If the drain is left in place, limit dwell time to 6 hours to reduce infection risk. [12]

*Initial ascitic-fluid studies and the decision each result changes. [10][11][12][19][23]*

| Test | Actionable result | Interpretation and next action |
| --- | --- | --- |
| Cell count and differential | Neutrophils >250/mm3 | Diagnose SBP and initiate treatment; do not await culture confirmation. [19] |
| Ascitic albumin plus same-day serum albumin | SAAG ≥1.1 g/dL | Supports portal-hypertensive ascites; integrate total protein and clinical context. [10][23] |
| Ascitic total protein | <2.5 g/dL with SAAG ≥1.1 g/dL | Pattern strongly supports cirrhosis with portal hypertension. [10] |
| Ascitic total protein | ≥2.5 g/dL with SAAG ≥1.1 g/dL | Pattern usually indicates right-heart failure; direct cardiac evaluation accordingly. [10] |
| Culture | Positive culture with PMN <250/mm3 | Bacterascites; treat if symptomatic, while asymptomatic patients should undergo repeat paracentesis. [13] |

## Use SAAG and ascitic protein to direct the etiologic workup

Classify portal-hypertensive versus nonportal ascites before committing to cirrhosis-directed therapy.

Calculate SAAG as serum albumin minus ascitic albumin. A SAAG ≥1.1 g/dL indicates portal hypertension and correlates with a hepatic vein–portal vein pressure gradient greater than 11 mm Hg; a SAAG <1.1 g/dL redirects the evaluation toward nonportal mechanisms. Although SAAG is highly useful, interpret it with the total clinical picture because exceptions occur. [10][23]

For high-SAAG ascites, ascitic total protein is the key discriminator. A protein concentration <2.5 g/dL supports cirrhosis and portal hypertension, whereas protein ≥2.5 g/dL usually indicates right-heart failure. A high-SAAG result therefore should not automatically be labeled cirrhotic ascites when cardiac congestion is plausible. [10]

For low-SAAG ascites, prioritize peritoneal malignancy, chronic peritoneal infection including tuberculosis, and nephrotic syndrome. Evaluate for nephrotic syndrome or protein-losing enteropathy when the clinical setting supports either diagnosis. Pancreatic ascites may produce an elevated PMN count but generally remains low-SAAG, so neutrophilia alone does not establish SBP in a nonportal fluid pattern. [10]
- Order ascitic cytology when a low-SAAG pattern or clinical course suggests peritoneal malignancy; malignant ascites reflects advanced malignant disease and may require repeated symptom-directed fluid management. [8][12]
- In milky fluid, measure ascitic triglycerides and investigate malignancy, cirrhosis, postsurgical or traumatic lymphatic injury, and infection according to context. Chylous ascites is typically defined by triglycerides >200 mg/dL. [15][16]
- Use imaging to assess liver morphology, portal-hypertensive features, malignancy, pancreatic disease, or cardiac congestion in parallel with fluid classification; ultrasound is recommended before paracentesis. [10]

*Etiologic branching by SAAG and ascitic total protein. [10][15][16][23]*

| Fluid pattern | Most likely mechanism or cause | Next diagnostic direction |
| --- | --- | --- |
| SAAG ≥1.1 g/dL; protein <2.5 g/dL | Cirrhosis with portal hypertension | Assess decompensation, infection, kidney function, and response to ascites treatment. [10] |
| SAAG ≥1.1 g/dL; protein ≥2.5 g/dL | Usually right-heart failure | Evaluate for cardiac congestion rather than assuming cirrhosis. [10] |
| SAAG <1.1 g/dL | Peritoneal malignancy, tuberculosis, nephrotic syndrome, or pancreatic ascites | Use clinical context to pursue cytology, chronic infection evaluation, renal protein-loss assessment, or pancreatic evaluation. [10] |
| Milky fluid; triglycerides >200 mg/dL | Chylous ascites | Evaluate for malignancy, cirrhosis-related portal hypertension, postoperative or traumatic lymphatic leak, and infection. [15][16] |

## Recognize and act on spontaneous bacterial peritonitis

The ascitic neutrophil count determines immediate management.

Diagnose SBP when ascitic fluid neutrophils exceed 250/mm3. This threshold applies whether neutrophils are measured microscopically or by flow cytometry-based automated counting; reagent strips do not have clear evidence for routine diagnosis. In a traumatic paracentesis with ascitic red cells >10,000/mm3, correct the PMN count by subtracting 1 PMN for every 250 red cells/mm3. [11][19]

Culture-negative neutrocytic ascites has PMN ≥250/mm3 with a negative culture and remains an infected-ascites phenotype requiring treatment. In contrast, monomicrobial nonneutrocytic bacterascites has a positive culture with PMN <250/mm3: treat symptomatic patients, but in asymptomatic patients repeat paracentesis and start antibiotics if the repeat PMN count reaches ≥250/mm3. [13]

In SBP with increased or rising serum creatinine, administer albumin 1.5 g/kg within 6 hours of diagnosis followed by 1 g/kg on day 3. This regimen targets the high-risk renal phenotype rather than routine albumin use for every infected ascites presentation. [2][3][17]
- Collect ascitic culture before antibiotics when feasible; bedside inoculation into aerobic and anaerobic bottles increases culture yield from approximately 50% to approximately 80% when PMN is ≥250/mm3. [11]
- For healthcare-associated or nosocomial SBP, choose empiric therapy using local susceptibility data; piperacillin-tazobactam is suggested in settings with low multidrug resistance, while ESBL-prevalent settings may require a carbapenem, with additional gram-positive multidrug-resistant coverage considered where prevalent. [17]
- If ascitic cultures are polymicrobial, consider procedural bowel puncture or another secondary intra-abdominal source rather than uncomplicated SBP. [13]

*Ascitic-fluid infection phenotypes and immediate action. [11][13][19]*

| Phenotype | Fluid findings | Management decision |
| --- | --- | --- |
| SBP | PMN >250/mm3 | Treat as SBP; culture result does not delay treatment. [19] |
| Culture-negative neutrocytic ascites | PMN ≥250/mm3 with negative culture | Manage as infected ascites requiring treatment. [13] |
| Monomicrobial nonneutrocytic bacterascites | Single-organism culture positive; PMN <250/mm3 | Treat if symptomatic; if asymptomatic, repeat paracentesis and treat if PMN becomes ≥250/mm3. [13] |
| Polymicrobial bacterascites | Multiple organisms; PMN <250/mm3 | Assess for needle-related gut puncture or another secondary source. [13] |

## Manage large-volume and refractory cirrhotic ascites

Paracentesis and albumin replacement are central when ascites is tense, symptomatic, or diuretic-refractory.

Large-volume paracentesis is standard care for large-volume ascites and is used with diuretic therapy when applicable. In diuretic-refractory ascites, remove as much fluid as feasible for symptom control. Bedside paracentesis is generally safe, and repeated therapeutic paracentesis is commonly used when fluid is refractory to fluid restriction and diuretics. [2][5][12]

After paracentesis removing >5 L, infuse 20% or 25% albumin at 8 g per liter of ascites removed. For removal of <5 L, consider the same 8 g/L replacement in acute-on-chronic liver failure or when post-paracentesis acute kidney injury risk is high. Albumin remains the preferred plasma expander in this setting. [2][3]

Consider TIPS in selected patients with refractory or recurrent ascites, and assess transplant candidacy at the same decision point. TIPS may improve ascites control and, in more recent randomized studies using contemporary selection and stent approaches, improved survival compared with large-volume paracentesis; selection is crucial because the earlier trials commonly excluded more severe liver disease. [3][6][9]
- Discuss TIPS with the transplant center before the procedure in transplant-eligible patients. [6]
- Treat bilirubin >50 micromol/L, platelets <75 × 10^9/L, current encephalopathy, active infection, progressive renal failure, severe systolic or diastolic dysfunction, and pulmonary hypertension as high-risk features that may predict limited TIPS benefit. [6]
- Monitor renal function, serum sodium, arterial pressure, and urine sodium because hyponatremia, low arterial pressure, increased creatinine, and low urine sodium predict poor prognosis in cirrhotic ascites. [17]

### Long-term albumin: selective and unsettled

Long-term albumin is not equivalent to post-paracentesis replacement. In the ANSWER trial of 442 patients with persistent ascites, 40 g human albumin weekly for up to 18 months was associated with a 38% lower mortality hazard and fewer refractory-ascites, renal, encephalopathy, and infection events. Its role across decompensated cirrhosis remains debated, so use should be individualized rather than substituted for evaluation of refractory ascites, TIPS suitability, or transplantation. [4]

*Procedure-centered escalation for cirrhotic ascites. [2][3][6][9][12]*

| Clinical situation | Primary action | Key guardrail |
| --- | --- | --- |
| Large, symptomatic ascites | Therapeutic large-volume paracentesis. [2][12] | Give 20% or 25% albumin 8 g/L removed when >5 L is removed. [2][3] |
| <5 L removed with ACLF or high post-paracentesis AKI risk | Consider albumin 8 g/L removed. [2][3] | Recommendation is weaker than for >5 L removal. [2][3] |
| Refractory or recurrent ascites | Consider TIPS and liver-transplant evaluation. [3][6][9] | Screen for encephalopathy, infection, renal decline, cardiac dysfunction, pulmonary hypertension, bilirubin >50 micromol/L, and platelets <75 × 10^9/L. [6] |
| Transplant-eligible patient considered for TIPS | Discuss TIPS with the transplant center. [6] | Do not treat TIPS as a substitute for transplant planning. [6][9] |

## Redirect management when ascites is nonportal or atypical

Fluid removal may relieve symptoms, but definitive control requires treating the driver.

A low-SAAG profile should prevent reflex escalation of portal-hypertension therapy. Peritoneal malignancy, chronic peritoneal infection, nephrotic syndrome, and pancreatic ascites each require a cause-specific diagnostic pathway; obtain cytology when malignancy is suspected, evaluate protein-loss disorders when indicated, and interpret pancreatic inflammation or leak in the setting of low-SAAG fluid. [10]

Malignant ascites is associated with advanced cancer and significant morbidity. Use paracentesis for symptom relief and coordinate disease-directed oncologic assessment rather than treating the fluid pattern as cirrhotic ascites. Diuretics are described as a treatment mainstay, but the expected response depends on the underlying physiology and should not delay diagnostic clarification. [8][12]

For chylous ascites, distinguish lymphatic obstruction or leak from portal-hypertensive lymphatic overload. In adults in Western settings, tumors, cirrhosis, and postoperative leakage are common causes; lymphangiography may be a therapeutic option for refractory lymphatic leakage in selected cases. [15][16]
- Rapid fluid reaccumulation, low SAAG, atypical imaging, or milky fluid should trigger reassessment for malignancy or lymphatic pathology rather than repeated empiric cirrhosis-directed management. [10][15][16]
- In suspected chylous ascites, triglycerides >200 mg/dL support the diagnosis but do not establish cause; actively exclude malignancy when nonportal etiologies are plausible. [16]

*Escalation triggers that should redirect the working diagnosis. [8][10][15][16]*

| Trigger | Concern | Next action |
| --- | --- | --- |
| SAAG <1.1 g/dL | Nonportal ascites | Prioritize malignancy, tuberculosis or other chronic peritoneal infection, nephrotic syndrome, and pancreatic causes. [10] |
| Milky fluid with triglycerides >200 mg/dL | Chylous ascites | Investigate malignancy, cirrhosis, postsurgical or traumatic lymphatic injury, and infection. [15][16] |
| High SAAG with protein ≥2.5 g/dL | Cardiac ascites | Evaluate for right-heart failure or congestive physiology. [10] |
| Clinical concern for cancer or low-SAAG pattern | Peritoneal malignancy | Obtain cytology and pursue malignancy-directed assessment. [8][10][12] |

## References
1. Cirrhosis - Guidelines | BMJ Best Practice — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-gb/278/guidelines
2. Guidelines on the management of ascites in cirrhosis - Gut — gut.bmj.com — https://gut.bmj.com/content/gutjnl/early/2020/10/15/gutjnl-2020-321790.full.pdf
3. Guidelines on the management of ascites in cirrhosis - Gut - The BMJ — gut.bmj.com — https://gut.bmj.com/content/70/1/9
4. chronic liver failure (ACLF) and the role of biomarkers - Gut — gut.bmj.com — https://gut.bmj.com/content/gutjnl/early/2024/03/25/gutjnl-2023-330584.full.pdf
5. Treatment of Patients with Cirrhosis — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMra1504367
6. Transjugular intrahepatic portosystemic stent-shunt in the ... - Gut — gut.bmj.com — https://gut.bmj.com/content/69/7/1173
7. Does This Patient Have Ascites? How to Divine Fluid in the Abdomen — jamanetwork.com — https://jamanetwork.com/journals/jama/fullarticle/397285
8. Malignant Ascites: New Concepts in Pathophysiology, Diagnosis ... — jamanetwork.com — https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/752267
9. Liver diseases: epidemiology, causes, trends and predictions - Nature — www.nature.com — https://www.nature.com/articles/s41392-024-02072-z
10. Unexplained ascites - Hernaez - 2016 - Clinical Liver Disease - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/cld.537
11. Serum-Ascites Albumin Gradient - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/serum-ascites-albumin-gradient
12. Performing Abdominal Paracentesis - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1555415522005104
13. Ascites - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/ascites
14. The Epidemiology of Ascites in a Multi‐Ethnic Asian Population - Sinnanaidu - 2025 - JGH Open - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/jgh3.70111
15. Intranodal lymphangiography in the treatment of chylous ascites - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S2173510718300843
16. Chylous Ascites From Cirrhosis-Related Portal... : ACG Case Reports Journal — journals.lww.com — https://journals.lww.com/acgcr/fulltext/2026/01000/chylous_ascites_from_cirrhosis_related_portal.22.aspx
17. Optimal Management of Cirrhotic Ascites: A Review for Internal Medicine Physicians - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC7805288
18. The AASLD Clinical Practice Guidelines: A Critical Review of Scientific Evidence and Evolving Recommendations - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC4613804
19. [PDF] EASL Clinical Practice Guidelines for the management of patients ... — easl.eu — https://easl.eu/wp-content/uploads/2018/10/decompensated-cirrhosis-English-report.pdf
20. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. - Abstract — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/20633946
21. [PDF] Hepatorenal-Cirrhosis-English-report.pdf - EASL — easl.eu — https://easl.eu/wp-content/uploads/2018/10/Hepatorenal-Cirrhosis-English-report.pdf
22. Cirrhosis & Complications Archives - EASL-The Home of Hepatology. — easl.eu — https://easl.eu/publication_topic/cirrhosis-complications
23. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020 — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC8280040
24. Diagnosis, Evaluation and Management of Ascites, Spontaneous ... — www.aasld.org — https://www.aasld.org/practice-guidelines/diagnosis-evaluation-and-management-ascites-spontaneous-bacterial-peritonitis

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.